Investors for Opioid & Pharmaceutical Accountability in the News

Read our recent press: 


Financial Times: J&J/Alex Gorsky: pay wrongly downplays negatives

BioSpace: J&J Shareholders Urged by Others to Reject CEO's $30 Million Payday

Reuters: J&J shareholders approve CEO Gorsky's near-$30 mln pay plan

Reuters: J&J execs get pay raises, but only after bruising shareholder 'Vote No' campaign

Equilar: Early Say on Pay Trends Show Tide Turning Toward More Shareholder Dissent

BMO Capital Markets – Podcast: What Can Investors Do About the Opioid Crisis? Nearly $30 million payday for J&J CEO Gorsky gets shareholder nod

The Washington Post: Drug distributor McKesson docked CEO’s pay over the opioid crisis. He still made $15 million.

Reuters: J&J investor calls on shareholders to reject CEO Gorsky's pay

CBSNews: Critics take shots at Johnson & Johnson CEO's $30 million payday

Reuters: ISS joins Glass Lewis in recommending vote against J&J CEO's pay package

Responsible Investor: Investors are putting Covid and public health on the ballot in 2021

Stat News: Lilly is a holdout among companies that agree to disclose when executive pay is clawed back

Reuters: Exclusive: J&J CEO pay irks investors upset with opioid lawsuits fallout

The Philadelphia Inquirer: Vanguard and BlackRock split in a close vote on CEO pay at drug distributor AmerisourceBergen

Stat news: AmerisourceBergen say-on-pay proposal squeaks by amid outrage over CEO compensation

Stat News: ‘Deeply problematic’: AmerisourceBergen rewards its CEO despite the ravages of the opioid crisis

The Philadelphia Inquirer:  ‘Remember to vote!’ The CEO’s $14.3M pay at drug distributor AmerisourceBergen inspires dueling campaigns

Bloomberg: Two Firms Lost Billions Over Opioids. CEOs Got Bonuses Anyway.

The Washington Post: The $14 million CEO: Drug distributor boosts executive’s pay despite historic opioid settlement

The Economist: How to design CEO pay to punish iniquity, not just reward virtue

The Wall Street Journal: Clawbacks Are Hard, So Companies Try Postponing Pay Instead 



MyChesCo: Treasurer Torsella Brings Shareholder Action for Gilead Oversight

The Providence Journal: RI treasurer joins effort to stop overpricing of COVID drug remdesivir

Responsible Investor: The opioid epidemic and anticompetitive practice risks in pharmaceuticals and healthcare: an investor response

Wespath: Shareholder Engagement – Success Stories

The Philadelphia Inquirer: Teamsters take aim at executive bonuses at drug distributor AmerisourceBergen 



ValueWalk: Shareholders told opioid companies they had an oversight problem

ThinkAdvisor: How ESG Investing Can Help Address the Opioid Crisis

Forward: ‘Jewish Values’ Investors Are Targeting An Israeli Company — For The First Time

Pittsburgh Post-Gazette: Mylan shareholders back proposal to change incentive pay rules for top executives

Morningstar: Investors Pressure Firms on Opioid Crisis

Chief Investment Officer: CalSTRS Tackles Opioid Crisis

Roll Call: Opioid maker Mallinckrodt to support lobbying disclosure

ProxyPreview: Opioid Crisis & Insulin Prices Prompt Shareholder Push For Big Pharma Board Accountability

Pensions & Investments: States are suing opioid manufacturers but their pension funds embrace them

GoLocalProv: Magaziner Calls for Opioid Distributor AmerisourceBergen to Address Risks

Vermont Catholic: Shareholder action pushes companies to address key social issues

CNBC: Investors demand Walgreens explain how it’s managing opioid crisis risks 



ISS Insights: Opioid Accountability: The Push for Better Risk Management Continues

State of Rhode Island: 2018 Shareholder Engagement Review


Press Releases:

Treasurer Magaziner: Shareholders Overwhelmingly Demand Action from Opioid Distributor after Company Fails to Block Vote at SEC

Independent Investors Support Shareholder Proposals on Opioids at AmerisourceBergen Shareholder Meeting

ISS, Glass Lewis Support Investors for Three Opioid Accountability Shareholder Proposals at AmerisourceBergen

Investors for Opioid Accountability/ IOA on Cardinal Health Annual Shareholder Meeting

$1.3 Trillion Investor Coalition Probes Pharma on Opioid Accountability


Sign Up for our eNewsletter

* indicates required